SECsense Logo

Oncolytics Biotech Inc. February 2025 Form 6-K: Key Financial Insights Revealed

$ONCY
Form 6-K
Filed on: 2025-02-25
Source
Oncolytics Biotech Inc. February 2025 Form 6-K: Key Financial Insights Revealed

The extracted key information and insights from the financial report (Form 6-K) for Oncolytics Biotech Inc. for the month of February 2025 are as follows:

  1. Document Type and Filing Date:
  • Type: Form 6-K
  • Filing Date: February 25, 2025
  1. Registrant Information:
  • Name: Oncolytics Biotech Inc.
  • Principal Executive Offices Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5
  1. Commission File Number:
  • 001-38512
  1. Submission Context:
  • This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
  • The report contains information that may be required under the rules of the home country exchange where the registrant's securities are traded.
  1. Exhibits:
  • Exhibit 99.1: Contains a press release, which is accessible via the link provided in the document.
  1. Signature:
  • The report was signed by Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc.
  1. Regulatory Compliance:
  • The filing indicates compliance with Regulation S-T regarding the submission of the Form 6-K in paper format as permitted under specific rules.
  1. Notes on Filing:
  • The document mentions that submission in paper is only allowed if it is to provide an attached annual report or if it is to furnish a report mandated by the laws of the registrant's home country.

This filing serves as an official communication to shareholders and potential investors, providing compliance with SEC regulations and updating stakeholders on relevant company information.